“…A unilateral, and often large, effusion may be the only visible abnormality, and emergence of a new effusion on a background of established pleural plaques is highly suspicious. Nodular pleural thickening, unilateral volume loss and fissural pleural thickening are all classically associated with MPM [ 16 ]; however, these are late radiographic features. Pleural plaques are consistent with asbestos exposure, but are commonly observed in patients who will never develop MPM [ 3 ].…”
Section: Mesotheliomamentioning
confidence: 99%
“…In addition to effusion, CT will often reveal nodular, enhancing pleural thickening. Mediastinal, circumferential and fissural pleural thickening are typical of MPM [ 16 , 17 ], but no CT parameter reliably differentiates MPM from secondary pleural cancers. CT is significantly limited by poor tissue contrast between MPM and adjacent soft tissues/loculated fluid, translating into poor sensitivity (58–68%) in large series [ 11 , 18 ].…”
The pleural space is a “potential” anatomical space which is formed of two layers: visceral and parietal. It normally contains a trace of fluid (∼10 mL in each hemithorax). Diseases of the pleura can manifest with thickening of the pleural membranes or by abnormal accumulation of air or liquid. Chest radiographs are often the first imaging tests to point to a pleural pathology. With the exception of pneumothorax, and due to the inherent limitations of chest radiographs, ultrasound and/or computed tomography are usually required to further characterise the pleural pathology and guide management. This review summarises the utility of different imaging tools in the management of pleural disease and discusses new and evolving tools in imaging of the pleura.
“…A unilateral, and often large, effusion may be the only visible abnormality, and emergence of a new effusion on a background of established pleural plaques is highly suspicious. Nodular pleural thickening, unilateral volume loss and fissural pleural thickening are all classically associated with MPM [ 16 ]; however, these are late radiographic features. Pleural plaques are consistent with asbestos exposure, but are commonly observed in patients who will never develop MPM [ 3 ].…”
Section: Mesotheliomamentioning
confidence: 99%
“…In addition to effusion, CT will often reveal nodular, enhancing pleural thickening. Mediastinal, circumferential and fissural pleural thickening are typical of MPM [ 16 , 17 ], but no CT parameter reliably differentiates MPM from secondary pleural cancers. CT is significantly limited by poor tissue contrast between MPM and adjacent soft tissues/loculated fluid, translating into poor sensitivity (58–68%) in large series [ 11 , 18 ].…”
The pleural space is a “potential” anatomical space which is formed of two layers: visceral and parietal. It normally contains a trace of fluid (∼10 mL in each hemithorax). Diseases of the pleura can manifest with thickening of the pleural membranes or by abnormal accumulation of air or liquid. Chest radiographs are often the first imaging tests to point to a pleural pathology. With the exception of pneumothorax, and due to the inherent limitations of chest radiographs, ultrasound and/or computed tomography are usually required to further characterise the pleural pathology and guide management. This review summarises the utility of different imaging tools in the management of pleural disease and discusses new and evolving tools in imaging of the pleura.
“…Chest radiography represents the first-level imaging modality for the detection of PM. According to the International Mesothelioma Interest Group (iMIG) Pleural Imaging Expert Panel, both frontal and lateral chest radiographs should be obtained taking care to include anterior and posterior costophrenic angles [ 16 ]. A unilateral pleural effusion is the most typical finding at presentation, occurring in a variable proportion of patients (ranging from 30 to 80%).…”
Section: Imaging Diagnosis: Which Modality?mentioning
confidence: 99%
“…Pleural plaques are thickened areas of parietal pleura made up of connective tissue that can become calcified, and represent the commonest radiographic manifestation of long-standing asbestos exposure, occurring in about 20% of cases [ 2 ]. However, radiographic findings are often nonspecific and vary depending on disease stage at diagnosis, prompting the use of second-level imaging tests to accurately assess disease burden and differentiate PM from nearby anatomic structures and other conditions [ 16 ]. Fig.…”
Section: Imaging Diagnosis: Which Modality?mentioning
Pleural mesothelioma (PM) is an aggressive disease that has a strong causal relationship with asbestos exposure and represents a major challenge from both a diagnostic and therapeutic viewpoint. Despite recent improvements in patient care, PM typically carries a poor outcome, especially in advanced stages. Therefore, a timely and effective diagnosis taking advantage of currently available imaging techniques is essential to perform an accurate staging and dictate the most appropriate treatment strategy. Our aim is to provide a brief, but exhaustive and up-to-date overview of the role of multimodal medical imaging in the management of PM.
“…Currently, there are several guidelines and consensuses both domestically and internationally that provide guidance for the clinical standard diagnosis and treatment of MPM 3–6 . However, there are still many issues that need to be confirmed and standardized in clinical practice, especially in the standardized application of new diagnostic techniques and treatment methods.…”
Malignant pleural mesothelioma (MPM) is a malignant tumor originating from the pleura, and its incidence has been increasing in recent years. Due to the insidious onset and strong local invasiveness of MPM, most patients are diagnosed in the late stage and early screening and treatment for high‐risk populations are crucial. The treatment of MPM mainly includes surgery, chemotherapy, and radiotherapy. Immunotherapy and electric field therapy have also been applied, leading to further improvements in patient survival. The Mesothelioma Group of the Yangtze River Delta Lung Cancer Cooperation Group (East China LUng caNcer Group, ECLUNG; Youth Committee) developed a national consensus on the clinical diagnosis and treatment of MPM based on existing clinical research evidence and the opinions of national experts. This consensus aims to promote the homogenization and standardization of MPM diagnosis and treatment in China, covering epidemiology, diagnosis, treatment, and follow‐up.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
